Ching-chung Hsiao

Linkou Branch
Taoyuan, TNQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

The benefit of LDL-C levels below 55 mg/dL in ESKD patients under statin treatment: A target trial emulation study.

The benefit of LDL-C levels below 55 mg/dL in ESKD patients under statin treatment: A target trial emulation study.

Journal: Atherosclerosis

Published: May 07, 2026

Pre-hemodialysis exercise training improves systemic aerobic capacity and platelet bioenergetic efficiency in patients with end-stage renal disease.

Pre-hemodialysis exercise training improves systemic aerobic capacity and platelet bioenergetic efficiency in patients with end-stage renal disease.

Journal: Life sciences

Published: February 04, 2026

Cardiorenal Outcomes of Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes Mellitus With Nephrotic-Range Proteinuria: A Multi-Institutional Target Trial Emulation.

Cardiorenal Outcomes of Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes Mellitus With Nephrotic-Range Proteinuria: A Multi-Institutional Target Trial Emulation.

Journal: Diabetes, obesity & metabolism

Published: January 31, 2026

Assessing the utility of fractional excretion of urea in distinguishing intrinsic and prerenal acute kidney injury in hospitalised patients: a systematic review and meta-analysis.

Assessing the utility of fractional excretion of urea in distinguishing intrinsic and prerenal acute kidney injury in hospitalised patients: a systematic review and meta-analysis.

Journal: BMJ open

Published: January 14, 2026

Hyperosmotic stress-induced impairment of erythrocyte deformability correlates with reduced aerobic capacity in end-stage renal disease.

Hyperosmotic stress-induced impairment of erythrocyte deformability correlates with reduced aerobic capacity in end-stage renal disease.

Journal: Microvascular research

Published: January 02, 2026

Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in dialysis patients with type 2 diabetes: a real-world propensity score-matched study.

Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in dialysis patients with type 2 diabetes: a real-world propensity score-matched study.

Journal: Clinical kidney journal

Published: December 20, 2025

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes.

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes.

Journal: Clinical pharmacology and therapeutics

Published: December 17, 2025

Cardio-renal outcomes in type 2 diabetes patients with advanced chronic kidney disease on SGLT2 inhibitors or GLP-1 receptor agonists.

Cardio-renal outcomes in type 2 diabetes patients with advanced chronic kidney disease on SGLT2 inhibitors or GLP-1 receptor agonists.

Journal: The American journal of medicine

Published: August 21, 2025

Clinical Outcomes of Ticagrelor versus Clopidogrel in Patients with Chronic Kidney Disease and Acute Myocardial Infarction: A Real-World Cohort Study.

Clinical Outcomes of Ticagrelor versus Clopidogrel in Patients with Chronic Kidney Disease and Acute Myocardial Infarction: A Real-World Cohort Study.

Journal: Cardiorenal medicine

Published: July 08, 2025

From gains to decline: effects of structured pre-dialytic exercise training and detraining on physical fitness, quality of life, and inflammation in haemodialysis patients.

From gains to decline: effects of structured pre-dialytic exercise training and detraining on physical fitness, quality of life, and inflammation in haemodialysis patients.

Journal: Journal of rehabilitation medicine

Published: June 04, 2025

Author Correction: SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM.

Author Correction: SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM.

Journal: Scientific reports

Published: April 11, 2025

Combining Ketoacid Analog Supplemented Low-Protein Diets with Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Diabetic Kidney Disease.

Combining Ketoacid Analog Supplemented Low-Protein Diets with Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Diabetic Kidney Disease.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: March 22, 2025

Showing 1-12 of 49

Last Updated: 09/26/2026